CoChat
Sign Up
Cited by 236Lymphoma Diagnosis and TreatmentMultiple Myeloma Research and TreatmentsViral-associated cancers and disorders

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

Open access
Ruan, Jia, Martin, Peter, Shah, Bijal, Schuster, Stephen J., Smith, Sonali M., Furman, Richard R., Christos, Paul, Rodriguez, Amelyn, Svoboda, Jakub, Lewis, Jessica, Katz, Orel, Coleman, Morton, Leonard, John P.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1505237PMC PMC4710541
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenalidomide plus rituximab as a first-line therapy. METHODS: We conducted a single-group, multicenter, phase 2 study with induction and maintenance phases. During the induction phase, lenalidomide was administered at a dose of 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles; the dose was escalated to 25 mg daily after the first cycle if no dose-limiting adverse events occurred during the first cycle and was reduced to 15 mg daily during the maintenance phase. Rituximab was administered once weekly for the first 4 weeks and then once every other cycle until disease progression. The primary end point was the overall response rate. Secondary end points included outcomes related to safety, survival, and quality of life. RESULTS: A total of 38 participants were enrolled at four centers from July 2011 through April 2014. The median age was 65 years. On the basis of the Mantle Cell Lymphoma International Prognostic Index scores, the proportions of participants with low-risk, intermediate-risk, and high-risk disease at baseline were similar (34%, 34%, and 32%, respectively). The most common grade 3 or 4 adverse events were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammatory syndrome ("tumor flare") (in 11%), anemia (in 11%), serum sickness (in 8%), and fatigue (in 8%). At the median follow-up of 30 months (through February 2015), the overall response rate among the participants who could be evaluated was 92% (95% confidence interval [CI], 78 to 98), and the complete response rate was 64% (95% CI, 46 to 79); median progression-free survival had not been reached. The 2-year progression-free survival was estimated to be 85% (95% CI, 67 to 94), and the 2-year overall survival 97% (95% CI, 79 to 99). A response to treatment was associated with improvement in quality of life. CONCLUSIONS: Combination biologic therapy consisting of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma. (Funded by Celgene and Weill Cornell Medical College; ClinicalTrials.gov number, NCT01472562.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1505237

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1200/JCO.20.5.1288 · DOI

Cited by

Sorted by citations

See all 236

Related

See all

Metadata

Authors
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., Katz, O., Coleman, M., & Leonard, J. P.
Affiliations
  • NewYork–Presbyterian Hospital (US)
  • Moffitt Cancer Center (US)
  • Abramson Cancer Center (US)
  • University of Chicago Medical Center (US)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2015-11-05
Volume
373
Issue
19
Pages
1835-1844
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa1505237
PMC
PMC4710541
OpenAlex
W2184668473
Cited by
236
References
31
Citations by year
2026: 2 · 2025: 10 · 2024: 12 · 2023: 9 · 2022: 21 · 2021: 19 · 2020: 41 · 2019: 28 · 2018: 30 · 2017: 33 · 2016: 30
FWCI
24.62
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Celgene
  • National Institutes of Health (KL2TR000458, UL1TR000457)
  • Weill Cornell Medical College (UL1 TR000457‐06)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Keywords
mantle cell lymphoma, lenalidomide, rituximab, first-line therapy, immunomodulators, anti-CD20 monoclonal antibody, overall response rate, progression-free survival, overall survival, adverse events, neutropenia, tumor flare, maintenance therapy, quality of life
MeSH terms
Rituximab, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Exanthema, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neutropenia, Quality of Life, Thalidomide, Survival Analysis, Lymphoma, Mantle-Cell, Intention to Treat Analysis, Antibodies, Monoclonal, Murine-Derived, Maintenance Chemotherapy, Induction Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review